Physician profile
Andrew D Mann
NPI 1740266436
$8,488.76
in general payments reported to CMS, 2019-2025
19 companies · $1,154 in 2025
The $1,154 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $716 · 2021: $1,396 · 2022: $1,180 · 2023: $1,511 · 2024: $1,485 · 2025: $1,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,142 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,141.72 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,495.45 | 2019-2025 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,403.92 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,313.41 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Abbvie INC. | $1,068.27 | 2021-2025 | |
| Lundbeck LLC | $629.16 | 2019-2024 | Rexulti |
| Axsome Therapeutics, INC. | $520.09 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $473.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $333.36 | 2019-2025 | Trintellix |
| Allergan, INC. | $222.73 | 2019-2020 | |
| Corium, LLC | $207.17 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $189.00 | 2024-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $143.01 | 2020-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $104.54 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Ironshore Pharmaceuticals INC. | $104.29 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $98.46 | 2024-2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $78.90 | 2020 | |
| Braeburn INC. | $54.56 | 2024 | Brixadi |
| Neurocrine Biosciences, INC. | $31.83 | 2019 | |
| Sage Therapeutics, LLC | $17.53 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.